In addition to further research on the early role of KRAS mutations in various cancers, it is a pertinent question whether KRAS inhibitors or precise microenvironmental modulation therapies should be explored, and how opportunities for their application in individuals at the early stages of tumor development can be identified. The gene discussed is KRAS; the disease is cancer.